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or cancer-specific survival after curative resection
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Background: The preoperative ratio of neutrophils to lymphocytes (NLR) has been proposed as a marker of poor
outcome in patients having a resection for colorectal cancer (CRC). This study investigated the association between
NLR and overall survival, cancer-specific survival and recurrent cancer in patients who had a potentially curative
resection for node-positive CRC.
Methods: Data on 322 patients were drawn from a prospectively recorded registry operated on between 1999 and
2007. Analyses of survival involved the Kaplan-Meier method, Cox regression and competing risks Cox regression.
Results: Increasing NLR as a continuous variable was independently though weakly associated with diminishing
overall survival after adjustment for other prognostic variables (HR 1.06, 95% CI 1.01-1.11, p = 0.013). Receiver
operating characteristic analysis to dichotomize NLR as a predictor of overall survival yielded relatively poor
sensitivity (55%), specificity (66%) and positive predictive value (56%, CI 47%-64%). Competing risks regression also
showed that NLR was not independently associated with recurrence at any site (HR 1.04, CI 0.97-1.11, p = 0.241)
or CRC-specific mortality (HR 1.02, CI 0.92-1.12, p = 0.782) but was associated with non-CRC mortality (HR 1.09,
CI 1.03-1.15, p = 0.004).
Conclusion: In patients with stage C tumor the weak link between NLR and overall mortality was not specific to
CRC but apparently arose because patients with an elevated inflammatory status preoperatively were likely to
progress to earlier death but not necessarily because of their cancer.
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Inflammation has been associated with the development
of numerous malignancies including colorectal cancer
[1]. In addition, evidence of an ongoing systemic inflam-
matory reaction, in particular the modified Glasgow
Prognostic Score (mGPS), has been shown to predict
earlier tumor relapse and mortality in operable colorec-
tal cancer patients [2,3]. The mGPS is a 3-point scale
and is derived from measurements of serum albumin* Correspondence: stephen.clarke@sydney.edu.au
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reproduction in any medium, provided the orand C-reactive protein (CRP) concentrations. However,
CRP is not routinely measured and thus is generally not
available in datasets of well-characterised historical cohorts.
The ratio of circulating neutrophils to lymphocytes
(NLR) is another indicator of systemic inflammatory
response and has been proposed as a routinely available
preoperative indicator of prognosis in patients undergoing
resection of primary colorectal cancer (CRC) [4-7]
(Table 1). The origin of this suggestion was a study of se-
rial postoperative observations of neutrophils and lympho-
cytes which showed that the ratio of these two factors was
an effective indicator of the intensity of physiological
stress in ICU patients after CRC resection or surgery for
abdominal sepsis or medical treatment of severe sepsis orl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.




















Walsh 2005 [7] Retrospective Colorectal A: 30 None specified For stages A-D: 3 patients Not 24 months Binary OS: yes OS: no
B: 80 specified < 5 vs. ≥ 5 CSS: yes CSS: no
C: 65 Pre-op




Leitch 2007 [10] Retrospective Colorectal I: 22 Infection or Not specified 11 Not 36 months Binary Stages I-III Stages I-III
II: 62 inflammatory patients specified < 5 vs. ≥ 5 OS: no OS: no
III: 65 conditions CSS: no CSS: no
IV: (liver mets) 84 Stage IV Stage IV
OS: no OS: no
Total 233 CSS: no CSS: no
Ding 2010 [12] Retrospective Colon IIA: 141 Adjuvant < 1 week Not Not Not Binary RFS: yes RFS: yes
CT before specified specified specified ≤ 4 vs. > 4
Multiple resection The precise
primaries, definition





Liu 2010 [5] Retrospective Rectum I: 17 Synchronous or Not specified Not All stage Not Binary CSS: no CSS: yes
II: 59 metachronous specified III or IV specified <2 vs. >2
III+IV: 47 cancer. Not
Total 123 Lost to follow specified
up when
exactly 2
Hung 2011 [9] Retrospective Colon II: 1040 Adjuvant Before Not Excluded 46 months Binary OS: yes OS: yes


















Table 1 Reports on the association between NLR and patient survival after resection of primary colorectal cancer (Continued)
registry precisely
data defined
Kwon 2012 [4] Retrospective Colorectal I: 13 Emergency 1 day before Not 150 Not Binary OS: yes OS: no
II: 91 Surgery. resection specified patients specified < 5 vs. ≥ 5 After
III: 88 Death < 30 adjusting for
IV: 8 days after platelet/




Chiang 2012 [11] Retrospective Colorectal Curative Anal cancer. Pre-op 124 73 11.6 Binary DFS: yes DFS: yes
only Primary site undefined patients patients months ≤3 vs. >3
undefined. indefinite. DFS not
Composite Synchronous not precisely







Mallappa 2013 [6] Retrospective Colorectal 297 patients. Inflammatory or Pre-op excluded Not Not Binary DFS: yes DFS: yes
haematological undefined specified specified < 5 vs. >5
Jass stage: disorders. DFS not
1: 90 Pre-op RT Not precisely
2: 71 Emergency specified defined
3: 58 resection. when
4: 78 Non-curative. exactly 5
Died ≤ 30 days
postoperatively.
NLR neutrophil/lymphocyte ratio, OS overall survival.
CSS cancer-specific survival, RFS recurrence-free survival.
DFS disease-free survival, PFS progression-free survival.
CB clinical benefit, TTLR time to local recurrence.
Mets metastasis, HNPCC Hereditary non-polyposis colorectal cancer.
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http://www.biomedcentral.com/1471-2407/13/442septic shock [8]. Subsequently, studies of patients with pri-
mary CRC have reported a statistically significant associ-
ation between preoperative NLR and overall survival
[4,7,9], although this association was not found in one
study [10]. Associations have also been reported between
NLR and recurrence-free or disease-free survival
[6,9,11,12] but not cancer-specific survival [7,10]. These
studies all examined both simple bivariate associations
between NLR and survival and multivariable models in-
cluding other known predictors of outcome, though the
association with overall survival did not persist in a
multivariable model in two cases [4,7] and another
study yielded the surprising finding of a multivariable
association between NLR and cancer-specific survival
despite no bivariate association [5]. The variability in
findings among these studies is perplexing and further
research on NLR and prognosis is clearly necessary. It
is of particular concern that all of the above studies
used an outmoded method of analysing the outcome
measures of cancer-specific survival. None employed
competing risks methods which are free of the biases
introduced by traditional methods [13] and are now
regarded as the most appropriate techniques for analy-
sing such data [14,15].
As mentioned, the preoperative NLR has been pro-
posed as a useful prognostic marker because it is based
on inexpensive data acquired routinely and early during
the investigation of patients for CRC and when taken to-
gether with pathological information from the operative
specimen, it may also yield useful independent informa-
tion on prognosis. Studies investigating this have been
based on patients with various pathological stage mixes
including TNM stage II only, [9] stage IIa only [12] and
stages I to IV [4-6,10], in one case including patients
with unresectable tumors [7]. In analysing the prognos-
tic potential of a marker it is important to choose a pa-
tient pool to which the marker can most appropriately
and productively be applied clinically. Patients with stage
I CRC have an almost uniformly good prognosis whereas
those with stage IV tumor invariably have poor out-
comes and thus a pre-operative NLR is unlikely to pro-
vide prognostic information that could alter treatment in
either of these patient groups, although it may predict
response to therapy in stage IV patients [16,17]. It is
more likely that NLR could provide additional prognos-
tic value after potentially curative resection of II or stage
III tumor. In particular, patients with stage III tumor
form a heterogeneous group and there is a need for
markers that can lead to more precise prognosis and
hopefully differentiate between patients who may benefit
from additional adjuvant systemic chemotherapy and
those who will not. Although the role of NLR in stage II
tumor has already been described [9,12], to our know-
ledge its ability to predict outcomes after potentiallycurative resection of lymph node positive CRC has not
been investigated.
All prior reports on NLR in primary CRC have
converted the continuous measure of NLR to a binary
variable in analyses, in most cases using the cutting
point of NLR < 5 versus ≥ 5 [4,6,7,9,10] as proposed by
Zahorec [8]. However, various other cutting points have
also been employed [5,11,12]. The point chosen to
dichotomize NLR values could potentially have an im-
portant influence on the findings of a study. The thresh-
old should not be chosen arbitrarily but should be
determined by an objective optimizing technique which
is relevant to the particular outcome under investigation,
as different thresholds may be appropriate for different
outcomes.
The aim of this study was to examine the association
between preoperative NLR and tumor recurrence, over-
all survival and colorectal cancer-specific survival after
resection of stage C CRC. A secondary aim was to inves-




Information on patients having a resection for CRC
performed by members of the Concord Hospital Depart-
ment of Colorectal Surgery has been entered into a pro-
spective computer database since 1971 [18,19]. The data
set contains details of patient characteristics, comorbi-
dity, presentation, investigations, surgical management,
complications, adjuvant therapy, pathology and follow-
up and has the approval of the South Western Sydney
Health Area Ethics Committee. Patients described in the
present study had a resection for stage C CRC between
November 1999 and December 2007 inclusive. All resec-
tions were performed by specialist colorectal surgeons
following a standardized procedure [20,21] and data ac-
quisition and recording was supervised by a single sur-
geon (P.H.C.).
Patients were excluded if they had had a colorectal
cancer previously or if they had adenomatous polyposis
coli, ulcerative colitis, Crohn’s disease or if they had
received preoperative chemoradiotherapy. Seven pa-
tients received postoperative radiotherapy but were not
excluded. Pathological examination of the resected spe-
cimen followed a standard protocol [18,22]. Only
adenocarcinomas (including mucinous and signet ring
carcinomas) were included in the data set. Where mul-
tiple tumors were present, only the lesion with the
most advanced stage was included. Tumor size was
measured as the greatest surface dimension and di-
chotomized as < 5 cm versus ≥ 5 cm. Blocks were
taken to demonstrate maximum direct tumor penetra-
tion of the bowel wall. Additional blocks were taken
Jankova et al. BMC Cancer 2013, 13:442 Page 5 of 13
http://www.biomedcentral.com/1471-2407/13/442specifically to demonstrate the relationship between
tumor and any adherent structure or tissue [23] as
well as lines of resection and the free serosal surface
[24]. Venous invasion referred to involvement of thick
or thin walled veins, either within or beyond the bowel
wall. When doubt existed as to whether a structure in-
volved was a vein, a negative finding was recorded. An
apical lymph node was defined as the most proximal
of any nodes found within 1 cm of the vessel ligation
at the apex of a vascular pedicle [25]. The proportion
of involved lymph nodes was calculated as the number
of positive nodes divided by the number of nodes
harvested expressed as a percentage and was dichoto-
mized at < 40% versus ≥ 40%. All pathology features
analysed were looked for in every specimen and their
presence or absence recorded explicitly and there were
no missing data on any pathology variable. In analyses,
all patient and tumor characteristics which were not
natural binary variables were dichotomized in order to
simplify comparisons of effect sizes between covariates
in multivariable survival models. Tumors were staged
according to the Australian Clinicopathological Staging
System for colorectal cancer which accommodates sub-
stages compatible with other clincopathological staging
systems such as TNM [26]. Patients selected for the
present study had tumors involving local lymph nodes
but without distant metastasis (stage C) but not in-
cluding any with frank tumor in a proximal, distal, cir-
cumferential or deep line of resection.
The NLR was defined as the absolute count of neutro-
phils divided by the absolute count of lymphocytes de-
termined from the full blood count routinely taken
within the week before resection. This information was
not recorded in the prospective registry of patients but
was available in hospital files from 1999 onwards,
though was unavailable for 10 patients.
Follow-up and assessment of survival and recurrence
Patients were seen at least six-monthly for the first two
years after resection and yearly thereafter until death or
December 31, 2010. Surveillance included clinical exa-
mination, sigmoidoscopy, a chest x-ray and serial CEA
measurements. For rectal cancer a CT scan was
performed annually as well as a colonoscopy, the latter
especially in those patients who had initially presented
with obstruction due to a stenotic tumor and in whom
examination of the proximal colon had not been pos-
sible. For colon cancer, colonoscopy was generally re-
peated at 3 to 5 years following resection. Recurrence
was defined as clinically or radiologically suspected or
biopsy proven tumor in the pelvis, perineal scar or peri-
toneal cavity, or newly diagnosed distant metastasis.
Cause of death was ascertained from the patient’s sur-
geon or family physician or hospital records or from aclose relative or, in a small number of cases, from the
national registry of causes of death.
Overall survival time was measured from the date of
resection to the date of death due to any cause with
times censored at last contact for patients who were lost
to follow-up or who remained alive at the close of study
in June 2012. Colorectal cancer-specific survival was
measured from resection until the date of death due to
colorectal cancer with times censored at last contact for
patients who were lost to follow-up or who remained
alive at the close of study. The survival times of patients
who died of causes other than colorectal cancer were
measured until the date of death and these patients were
coded as having experienced a competing risk in regres-
sion analyses. Time to recurrence was measured until
the date of diagnosis of recurrence except for seven pa-
tients who died of CRC but whose precise recurrence
date was not known, in which cases the date of death
was substituted. Times were censored at last contact for
patients who were lost to follow-up or who remained
alive and recurrence-free at the close of study. Patients
who died without recurrence were classified as having
experienced a competing risk in regression analyses.
Statistical analysis
All analyses were conducted on the basis of intention to
treat. Because of the markedly skewed distribution of
NLR, associations between it and other covariates were
assessed by the Mann-Whitney U test. Proportional haz-
ards regression or competing risk regression was used to
assess the effect of NLR as a continuous variable on sur-
vival time and also for comparisons of survival time
between strata of binary variables. In multivariable
modelling, all covariates having an association with
survival with a Wald test p value < 0.1 were entered
into an initial regression model which was then re-
duced by sequential removal of covariates with a p value
of > 0.05, beginning with the highest p value until a
provisional final model containing only covariates with a
p value ≤ 0.05 was attained. Excluded variables were then
reintroduced singly into this model but none achieved
significance. The assumption of proportional hazards for
the continuous version of NLR was assessed by inspec-
tion of Schoenfeld residuals, and for dichotomous covari-
ates by examination of log cumulative hazard plots for
parallelism and in no case was it materially violated in
any variable included in a regression model. Possible
interactions between NLR and other covariates were
examined by introducing product terms singly into the
final model but no significant interactions were identified.
Two different methods were used in an attempt to
identify an optimal cutting point for NLR as a dichoto-
mous predictor of overall survival time. The first was the
conventional ROC curve method with death due to any
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that all patients remain in the calculations whether or not
their survival times are censored. The second method,
based on Kaplan-Meier curves and proportional hazards
regression, does take account of censoring. NLR was first
split at 0 to 1.49 versus ≥ 1.5 and Kaplan-Meier curves
and the hazard ratio, 95% confidence interval and Wald p
value were calculated. The cutting point was then raised in
steps of 0.5 (0-1.99 vs. ≥ 2, 0-2.49 vs. ≥ 2.5, etc.) and the re-
sults recalculated at each step in order to identify the
threshold giving the greatest separation of curves with the
lowest p value. The same process was applied in both a bi-
variate and a multivariable model.
The level for two-tailed statistical significance was p ≤
0.05 with confidence intervals (CI) at the 95% level. Ana-
lyses were performed with SPSS version 20 (IBM) andTable 2 Clinical and pathology characteristics of 322 patients
these characteristics and NLR
Total n = 322 n (%
Male 179 (55.
Female 143 (44.
Age ≥ 75 years 108 (33.
Age < 75 years 214 (66.
Rectal tumor 127 (39.
Colonic tumor 195 (60.
Tumour size ≥5cm 137 (42.
Tumour size <5cm 185 (57.
Mucinous or signet ring 34 (10.
Other adenocarcinoma 288 (89.
Direct spread beyond muscularis propria 271 (84.
Not beyond muscularis propria 51 (15.
Apical node involved 30 ( 9.
Not involved 292 (90.
≥ 4 nodes involved 102 (31.
< 4 nodes involved 220 (68.
≥ 40% of nodes involved 60 (18.
< 40% of nodes involved 262 (81.
Poorly differentiated 66 (20.
Moderately or well differentiated 256 (79.
Venous invasion 64 (19.
No venous invasion 258 (80.
Free serosal surface involved 76 (23.
Not involved 246 (76.
Adjacent structure infiltrated 23 ( 7.
Not infiltrated 299 (92.
Postoperative chemotherapy 197 (61.
No postoperative chemotherapy 125 (38.
Number, (%).Stata release 12 (Stata Corporation, College Station, TX,
2011).
Results
During the study period 1388 patients had a resection
for colorectal cancer. Of these, 1011 were excluded be-
cause their tumor was not stage C; 12 were excluded be-
cause of previous CRC; 3 because of inflammatory bowel
disease and 1 because of adenomatous polyposis coli. Of
the 361 patients remaining, preoperative haematology
results were not available retrospectively for 10 and 29
were excluded because they had received neoadjuvant
chemoradiotherapy, leaving 322 for analysis. Characteris-
tics of these patients are shown in Table 2.
The distribution of neutrophils ranged from 1.7 to
12.8 with a mean of 4.7 (SD 1.8), a median of 4.3 andwith stage C colorectal cancer and association between
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cytes ranged from 0.3 to 3.8 with a mean of 1.7 (SD 0.6),
a median of 1.6 and was approximately bell-shaped with
slight positive skewness (0.7). The NLR ranged from 0.7
to 28.5 with a mean of 3.3 (SD 2.7), a median of 2.7 and
very marked positive skewness (5.0).
Among the 14 clinical and tumor characteristics exa-
mined, NLR was significantly higher in patients aged
years 75 or older; for colonic tumors; for tumors ≥ 5 cm;
when an apical node was involved; for tumors with ≥ 40%
of nodes involved; for poorly differentiated tumors; when
a free serosal surface was involved; when an adjacent
structure was infiltrated by tumor, and in patients who had
not received postoperative chemotherapy (Table 2).
At the close of the study in June 2012, 6 patients (1.9%)





Neutrophil/lymphocyte ratio 322 141
Male 179 79
Female 143 62
Age ≥ 75 years 108 75
Age < 75 years 214 66
Rectal tumor 127 54
Colonic tumor 195 87
Tumor diameter ≥ 5cm 137 62
< 5cm 185 79
Mucinous or signet ring 34 19
No 288 122
Direct spread beyond muscularis propria 271 126
No 51 15
Apical node involved 30 18
No 292 123
≥ 4 nodes involved 102 58
No 202 83
≥ 40% of nodes involved 60 41
No 262 100
Poorly differentiated 66 42
No 256 99
Venous invasion 64 33
No 258 108
Free serosal surface involved 76 47
No 246 94
Adjacent structure infiltrated 23 17
No 299 124
Postoperative chemotherapy 197 61
No 125 80resection, 3 (0.9%) had been lost to follow-up after 5.9,
31.6 and 51.1 months respectively and 135 had died after a
median of 34.7 months (range 0.7 to 138.3 months). Me-
dian survival time in the 191 patients who remained alive
and were not lost was 82.2 months (range 34.3 to 146.8
months).
Overall survival
A Cox regression model with NLR as the single, continuous
covariate showed that overall survival diminished significantly
as NLR increased (hazard ratio [HR] 1.11, 95% CI 1.06-1.15,
p < 0.001) (Table 3). Other characteristics having a significant
bivariate association with diminished overall survival were
age ≥ 75 years, direct spread beyond the muscularis
propria, apical node involvement, ≥ 40% of nodes involved,
adjacent structure infiltrated by tumor, absence of adjuvantures and overall survival
f Bivariate association HR,
(95% CI), Wald p
Multivariable association HR,
(95% CI), Wald p
1.11 (1.06–1.15) p < 0.001 1.06 (1.01–1.12) p= 0.013
1.04 (0.74–1.45) p = 0.831 --
3.32 (2.37–4.63) p < 0.001 2.15 (1.42–3.27) p < 0.001
0.88 (0.62–1.23) p = 0.446 --
1.12 (0.81–1.57) p = 0.490 --
1.35 (0.83–2.20) p = 0.224 --
2.02 (1.18–3.45) p = 0.010 2.04 (1.18–3.54) p = 0.011
1.80 (1.08–3.00) p = 0.009 2.03 (1.22–3.39) p = 0.007
2.01 (1.43–2.81) p < 0.001 --
2.71 (1.88–3.91) p <0.001 2.52 (1.71–3.70) p <0.001
2.12 (1.47–3.04) p <0.001 --
1.44 (0.98–2.13) p = 0.066 --
2.36 (1.65–3.35) p < 0.001 --
3.16 (1.90–5.25) p < 0.001 2.88 (1.71–4.86) p <0.001
0.61 (0.26–0.51) p < 0.001 0.56 (0.37–0.85) p = 0.006
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nodes, and involvement of a free serosal surface, however
a multivariable model showed that the last three did not
have significant independent effects (Table 3). It was con-
cluded that increasing NLR was independently associated
with diminishing overall survival after adjustment for other
prognostic variables.
The results of the search for the optimal threshold for
dichotomizing NLR in relation to overall survival time
were unconvincing. The ROC curve method yielded an
optimum cutting point at an NLR of 2.8 (Figure 1), though
the ROC curve lay almost parallel to and not greatly dis-
tant from the null curve over the range from NLR = 2.4 to
3.8. At the optimum threshold of 2.8 the sensitivity was
55% (CI 47-64%), the specificity was 66% (CI 58-73%), the
negative predictive value was 65% (CI 58-72%) and the
positive predictive value was 56% (CI 47-64%).
Using the alternate method for fixing the threshold, the
bivariate hazard ratio became significant at an NLR
threshold of ≥ 2.5 (HR 1.96, CI 1.37-2.79, p < 0.001) and
increased to 2.84 (CI 1.74-4.42, p < 0.001) at an NLR
threshold of ≥ 7 but only 12 of the total of 141 deaths oc-
curred to patients above this point (Table 4), indicating
that high NLR defined by this threshold was an unsatisfac-
tory predictor of death. From this analysis of survival time
to death from any cause using two different methods it
was concluded that no clearly distinctive optimum thres-
hold could be identified.Figure 1 ROC curve for the NLR as a predictor of death due to
any cause. The optimum threshold of 2.8 is indicated by A, at
which point the positive predictive value was 56% (95% CI 47%-
64%). B indicates a threshold of 3.8, at which the positive predictive
value was 63% (CI 52%-74%). C indicates a threshold at 2.5%, at
which point the positive predictive value was 52% (CI 45%-60%).Colorectal cancer-specific death
The cause of death could not be determined for 13 de-
ceased patients, who were excluded, leaving 309 for ana-
lysis of colorectal cancer-specific death. Eighty-six
patients died of colorectal cancer, 42 died of other
causes and 181 remained alive at last contact. A compe-
ting risks regression model with NLR as the single, con-
tinuous covariate showed that the cumulative incidence
of CRC-specific death increased as NLR increased (HR
1.07, CI 1.003-1.13, p = 0.038). However this association
disappeared (HR 1.01, CI 0.92-1.12, p = 0.782) in a mul-
tivariable model into which NLR was forced (Table 5).
The statistically significant covariates in this model were
involvement of ≥ 40% of nodes, poor differentiation and
infiltration of an adjacent structure or organ (Table 5).
Because there was no significant independent association
between NLR and cancer-specific survival, no attempt
was made to find the optimal threshold for dichotomi-
zing NLR in this context.
The association between NLR and death was further
examined in a regression model with non-CRC death
classified as the event and death due to CRC as the com-
peting risk (Table 5). Here, NLR was significantly and in-
dependently associated with non-CRC death (HR 1.09,
CI 1.03-1.15, p = 0.004), along with male sex and age
≥ 75 years. Postoperative chemotherapy appeared to pro-
tect against death from other causes, presumably because
such treatment was generally confined to “fit patients”
who were not at great risk of non-cancer death.
The interpretation of these competing risk regression
models is that NLR was not an independent prognostic
factor for colorectal cancer death but was a prognostic
factor for death due to other causes.Recurrence
Eleven deceased patients who had not had a recurrence
and whose cause of death was unknown were excluded
from analysis of recurrence because it was unknown
whether their death was due to recurrent CRC. In the
remaining 311 there were 108 recurrences: 16 local only,
84 systemic only and 8 with both local and systemic recur-
rence. Thirty-nine patients died without recurrence an
164 remained alive without known recurrence at last con-
tact. The median time to recurrence was 15 months
(range 1 – 60 months) and the follow-up time of censored
patients who were not lost was 82 months (range 34 to
147 months). A regression model with non-CRC death as
a competing risk showed no bivariate association between
NLR and recurrence (HR 1.04, CI 0.97-1.11, p = 0.241,
Table 6) and a multivariable model showed that ≥ 40% of
nodes involved, poor differentiation, involvement of a free
serosal surface and infiltration of an adjacent structure or
organ were independently associated with recurrence but
Table 4 Association between overall survival and NLR at progressive thresholds for dichotomizing NLR
NLR dichotomy Patients number (%) n = 322 Deaths n = 141 Bivariate hazard ratio, (CI), Wald p
<1.5 30 ( 9) 13
≥1.5 292 (91) 128 1.14 (0.64–2.01) 0.6584
<2.0 75 (23) 26
≥2.0 247 (77) 115 1.40 (0.91–2.14) 0.1229
<2.5 138 (43) 45
≥2.5 184 (57) 96 1.96 (1.37–2.79) 0.0002
<3.0 187 (58) 68
≥3.0 135 (42) 73 1.88 (1.35–2.61) 0.0002
<3.5 257 (80) 101
≥3.5 65 (20) 40 2.15 (1.53–3.01) <0.0001
<4.0 268 (76) 107
≥4.0 83 (24) 50 2.07 (1.43–2.98) 0.0001
<4.5 273 (85) 110
≥4.5 49 (15) 31 2.07 (1.39–3.09) 0.0004
<5.0 287 (89) 117
≥5.0 35 (11) 24 2.48 (1.60–3.86) 0.0001
<5.5 293 (91) 120
≥5.5 29 ( 9) 21 2.78 (1.74–4.42) <0.0001
<6.0 298 (93) 124
≥6.0 24 ( 7) 17 2.54 (1.53–4.23) 0.0003
<6.5 302 (94) 128
≥6.5 20 ( 6) 13 2.12 (1.20–3.76) 0.0100
<7.0 306 (95) 129
≥7.0 16 ( 5) 12 2.84 (1.57–5.15) 0.0006
Jankova et al. BMC Cancer 2013, 13:442 Page 9 of 13
http://www.biomedcentral.com/1471-2407/13/442NLR, when forced into this model, was not (HR 0.99,
CI 0.90-1.08, p = 0.772).
Discussion
In this study of patients with stage C CRC, increasing
preoperative NLR was independently associated with di-
minished overall survival after adjustment for other in-
dependent prognostic variables. Findings on overall
survival are inconsistent in other reports. Only Hung
et al. have shown results equivalent to ours, albeit in pa-
tients with stage II colon cancer [9]. Walsh et al. [7] and
Kwon et al. [4] found a bivariate but no multivariable as-
sociation between NLR and overall survival in patients
with stages I to IV tumor whereas Leitch et al. found
neither in a similar patient pool [10]. Clearly overall sur-
vival is an important outcome for patients as it encom-
passes potential mortality arising both from the CRC
itself and from treatment as well as from other causes
which may be tangentially associated (e.g. hospital-
acquired infection or other iatrogenic illness). Further-
more, the prime concern for patients is how long they
survive, not what causes their death. It is striking that
these different studies have yielded such inconsistentresults on the association between NLR and overall sur-
vival; however this may be arise from the mixed nature
of these other populations, particularly in terms of
tumor stage. There are recent data that have linked NLR
levels with outcomes following coronary events and pro-
cedures and these data might be indicative of the types
of non-cancer related problems that could be influencing
non-cancer induced mortality in this and other cohorts
[27]. Traditionally, assessments of performance status
have been linked to survival outcomes in cancer and it is
possible that inflammatory markers might provide a less
subjective equivalent of performance status. In previous
studies from our group, inflammatory markers have cor-
related well with performance status scores [28]. The
relatively poor (though statistically significant) corre-
lation between NLR and OS could have been influenced
by the fact patients coming to surgery tend to be rela-
tively fit, therefore reducing number of unwell patients
who would be more likely to have high NLR levels. Fur-
thermore, in our practice, the proportion of patients
having emergency surgery is very low.
Some authors have reported on the outcomes of CRC-
specific survival [5,7,10] or disease -free survival [6,9,11]
Table 5 Association between NLR, clinical and pathology features and death due to colorectal cancer with death due
to other causes as a competing risk and association with death due to other causes with death due to colorectal
cancer as a competing risk
Death due to CRC
Bivariate association
Death due to CRC
Multivariable association
Death due to other causes
Bivariate association
Death due to other causes
Multivariable association
HR, (95% CI), Wald p HR, (95% CI), Wald p HR, (95% CI), Wald p HR, (95% CI), Wald p
Neutrophil/lymphocyte
ratio
1.07 (1.003–1.13) 0.038 1.01 (0.92–1.12) 0.782 1.09 (1.02–1.17) 0.013 1.09 (1.03–1.15) 0.004
Male 0.74 (0.48–1.12) 0.154 -- 1.91 (1.00–3.65) 0.051 2.32 (1.23–4.36) 0.009
Female
Age ≥ 75 years 1.77 (1.15–2.72) 0.009 -- 5.72 (2.98–10.95) <0.001 2.10 (1.03–4.30) 0.042
Age < 75 years
Rectal tumor 0.89 (0.58–1.38) 0.602 -- 1.05 (0.57–1.93) 0.870 --
Colonic tumor
Tumor diameter ≥ 5cm 1.09 (0.71–1.67) 0.696 -- 1.32 (0.72–2.42) 0.365 --
< 5cm




2.52 (1.19–5.33) 0.015 -- 1.21 (0.52–2.78) 0.661 --
No
Apical node involved 2.30 (1.23–4.27) 0.009 -- 0.71 (0.22–2.30) 0.567 --
No
≥ 4 nodes involved 2.27 (1.49–3.46) <0.001 -- 1.14 (0.60–2.17) 0.691 --
No
≥ 40% of nodes
involved
3.18 (2.04–4.96) <0.001 2.91 (1.79–4.74) <0.001 0.93 (0.40–2.13) 0.863
No
Poorly differentiated 2.63 (1.68–4.11) <0.001 2.01 (1.24–3.26) 0.005 1.02 (0.48–2.15) 0.966 --
No












0.79 (0.51–1.21) 0.279 -- 0.12 (0.05–0.26) <0.001 0.17 (0.07–0.39) <0.001
No
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http://www.biomedcentral.com/1471-2407/13/442or recurrence free survival [12], presumably because it is
believed that these outcomes will enable a more specific
assessment of the link between NLR and response to
CRC. Results for CRC-specific survival are no more con-
sistent than for overall survival; Leitch et al. found no
association with NLR, [10] Walsh et al. found a bivariate
but no multivariable association [7], and Liu et al. found
a multivariable but no bivariate association [5]. All threeof these studies have the technical problem that the sur-
vival times of patients who died of causes other than
CRC were censored at the date of death, which would
lead to an inflated estimate of the incidence of death due
to CRC [13,14]. This arises because, in standard time-to
-event analysis, it is assumed that all censored patients
remain equally at risk of death due to CRC after the
time of last contact but this of course is incorrect for
Table 6 Association between NLR, clinical and pathology features and any recurrence with death due to other causes






(95% CI), Wald p
Multivariable association HR,
(95% CI), Wald p
Neutrophil/lymphocyte ratio 311 108 1.04 (0.97–1.11) 0.241 0.99 (0.90–1.08) 0.772
Male 171 56 0.81 (0.56–1.19) 0.291 --
Female 138 52
Age ≥ 75 years 98 40 1.31 (0.88–1.94) 0.178 --
Age < 75 years 211 68
Rectal tumor 124 46 1.09 (0.74–1.60) 0.676 --
Colonic tumor 185 62
Tumor diameter ≥ 5cm 134 49 1.21 (0.82–1.77) 0.335 --
< 5cm 175 59
Mucinous or signet ring 32 15 1.45 (0.87–2.42) 0.153 --
No 277 93
Direct spread beyond muscularis
propria
260 97 2.14 (1.15–4.00) 0.017 --
49 11
No
Apical node involved 29 15 1.95 (1.10–3.45) 0.022 --
No 280 93
≥ 4 nodes involved 98 47 1.89 (1.29–2.77) 0.001 --
No 211 61
≥ 40% of nodes involved 56 32 2.36 (1.56–3.55) <0.001 1.87 (1.17–3.01) 0.009
No 255 76
Poorly differentiated 64 34 2.09 (1.39–3.13) <0.001 1.66 (1.07–2.57) 0.024
No 247 74
Venous invasion 61 26 1.50 (0.95–2.36) ).080 --
No 248 82
Free serosal surface involved 73 41 2.66 (1.80–3.95) <0.001 1.83 (1.18–2.84) 0.007
No 236 67
Adjacent structure infiltrated 22 16 3.86 (2.19–6.79) <0.001 2.93 (1.58–5.44) 0.011
No 287 92
Postoperative chemotherapy 195 71 1.18 (0.79–1.77) 0.407 --
No 114 37
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problem is to use competing risks Cox regression in
which patients who die of causes other than the cause of
interest are not censored but instead removed from the
calculations at the time of death. If the proportion of all
deaths due to other causes is either very large or very
small, use of the competing risks method may be irrele-
vant; in other circumstances competing risks regression
is both appropriate and necessary. In our study 33% of
all deaths were due to causes other than CRC and com-
peting risks regression showed no statistically significant
association between NLR and CRC-specific mortality
after adjustment for other prognostic factors. On theother hand, NLR was shown to be an independent prog-
nostic factor for deaths due to other causes.
The outcome of recurrence-free survival was examined
in one study [12] and disease-free survival in three
[6,9,11], though in no case were these defined explicitly
in terms of which patients had censored survival times.
This is important because various and sometimes
contradictory definitions of these concepts and of time
to recurrence exist [29] and the results of Kaplan-Meier
and Cox regression analyses of recurrence will vary, de-
pending on the definition used. These definitional com-
plexities are avoided by using competing risk methods in
which patients who have a recurrence are coded as
Jankova et al. BMC Cancer 2013, 13:442 Page 12 of 13
http://www.biomedcentral.com/1471-2407/13/442failures, those who are lost or remain alive without re-
currence are censored and those who die of other
causes are deemed to experience a competing risk.
Ours is the first report to use the contemporary statis-
tical method of competing risks Cox regression to ana-
lyse the association between NLR and CRC-specific
survival and recurrence. With this method we found no
association, either bivariate or multivariable, between
NLR and either death due to CRC or recurrence.
Most other studies of NLR in primary CRC have di-
chotomized NLR at < 5 versus ≥ 5 [4,6,7,9,10] as pro-
posed by Zahorec [8], although a cutting point at < 2
versus > 2 (sic) was used by Liu et al. because this was
approximately the upper limit in their normal control
patients [5]. ROC analysis was used to set the threshold
in two studies, producing NLR cutting points of ≤ 4 ver-
sus > 4 [12] and ≤ 3 versus > 3, [11] in both cases
resulting in the conclusion that NLR was an independ-
ent prognostic factor for poor outcome. Our own at-
tempt at using ROC analysis to determine an optimal
for NLR prediction of overall survival was equivocal; no
single, clear-cut solution could be found. This was be-
cause the association between NLR and survival, albeit
statistically significant, was weak. We concluded that,
while NLR is a weak independent predictor of overall
mortality after resection of stage C CRC, this is because
it predicts death from other causes, not because it pre-
dicts recurrence or cancer-related death. As the weak as-
sociation between NLR and overall mortality prohibits a
clear-cut differentiation of NLR into “high” and “low”
ranges of values, the sensitivity and specificity of any
such split will be poor and the positive and negative pre-
dictive values will be close to 50%, meaning that such a
test would have no clinical value. Despite the optimistic
conclusions of Chiang et al. [11] and Ding et al. [12] re-
garding their analyses, in both cases their ROC curves
depart only slightly from the null diagonal over a wide
range of sensitivities, clearly showing that the chosen
optimum cutting points give poor differentiation be-
tween “high” and “low” values of NLR and hence would
yield very poor sensitivity, specificity and predictive
values if the authors had given all of these measures. A
further reservation about the use of ROC curves in this
context is that the outcome variable conventionally used
is simply the crude death rate (or crude recurrence)
which ignores both the censoring of survival times and
the problem of competing risks regarding CRC-specific
survival or recurrence.
An important issue is the particular pool of patients in
which the NLR has been investigated.
Some studies include stage I patients [4-7,10] which is
unlikely to be productive because of the almost univer-
sally good prognosis in such patients. The same studies
also include stage IV patients despite their alreadyknown very poor prognosis. Although the NLR is un-
likely to have any prognostic importance in stage IV it is
possible that it may have predictive significance for out-
comes from chemotherapy in such patients [17] and fur-
ther investigations appear justifiable. It is likely that in
stage IV patients there is a greater prevalence of cancer-
associated inflammation than in stage III patients simply
because of the widespread nature of their disease. Hence,
it is possible that high levels of NLR are more likely to
predict overall poor outcome in advanced cancer patient
populations and therefore assist in the more objective
selection of patients to receive or not to receive pallia-
tive chemotherapy. We had hoped that NLR levels might
assist in defining groups more likely to benefit from ad-
juvant chemotherapy in patients with stage III cancers;
however this has not been demonstrated in the current
cohort.
Conclusion
In a large pool of well-documented patients who had a
resection for stage C CRC and using contemporary com-
peting risks survival methods we found that an elevated
NLR was independently associated with diminished
overall survival. However there was no association be-
tween NLR and either tumor recurrence or CRC-specific
death but elevated NLR was independently associated
with non-cancer death. Thus the link between NLR and
overall mortality was not specific to colorectal cancer
but apparently arose because patients with an elevated
inflammatory status preoperatively were likely to pro-
gress to earlier death, but not necessarily because of
their cancer.
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